secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-265810
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind Q3 revenue $82.1M (+17% YoY); completes scPharma acquisition
---------------------------------------------------------------------

- Q3 2025 revenues $82.1M (+17% YoY); YTD revenues $237.0M (+14%).
- GAAP net income $8.0M ($0.03 EPS) vs $11.6M in Q3 2024; non-GAAP net income $22.4M ($0.07) +45%.
- Completed scPharmaceuticals acquisition Oct 7 with ~$133.2M cash & $250M in delayed draw term loans.
- Afrezza pediatric sBLA accepted (PDUFA May 29, 2026); FUROSCIX sNDA submitted; MNKD-101 & MNKD-201 trials advancing.
- Appointed Dr. Ajay Ahuja as CMO; cash & investments $286.3M at Sep 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000119312525265810/0001193125-25-265810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000119312525265810/mnkd-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-265810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer